International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis

An International Non-Interventional Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis Treated With Oralair®.

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02041624

Acronym

ALTO

Enrollment

740

Registered

2014-01-22

Start date

2014-05-31

Completion date

2015-12-31

Last updated

2016-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis Due to Grass Pollens

Keywords

allergic, rhinitis, conjunctivitis, grass pollen, Allergen ImmunoTherapy (AIT), grass mix

Brief summary

The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.

Detailed description

Primary objective: To describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass pollen season in real-life settings. Secondary objectives: \- To describe the patient's perceived effectiveness of ORALAIR® in allergic rhinoconjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient of 5 years of age and older at the date of the screening visit * Patient with proven allergic rhino-conjunctivitis due to grass pollen * Patient eligible for a grass-pollen Allergen ImmunoTherapy (AIT) * Patient whose physician prescribed ORALAIR® independently of the study, before the beginning of the grass-pollen season

Exclusion criteria

* Patient participating in a clinical trial or in an epidemiological study

Design outcomes

Primary

Measure	Time frame	Description
Health related quality of life	patients will be followed for the duration of the treatment, an expected average of 6 months/year	The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.

Secondary

Measure	Time frame	Description
Treatment Effectiveness	patients will be followed for the duration of the treatment, an expected average of 6 months/year	To describe the patient's perceived effectiveness of ORALAIR® in allergic rhino-conjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Countries

France

Outcome results